A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys

International Journal of Toxicology

Volumn 29, Issue 3, 2010, Pages 259-267

  Braen, Angélique P J M ^a   Perron, Josée ^b   Tellier, Pierre ^b   Catala, Anthony R ^a   Kolaitis, Gerry ^a   Wanping Geng, ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Brain; Intrathecal; Toxicity; Trastuzumab

Indexed keywords

TRASTUZUMAB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN WEIGHT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MONKEY; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NONHUMAN; PATHOLOGICAL ANATOMY; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BRAIN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CATHETERS, INDWELLING; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; INFUSIONS, PARENTERAL; MACACA FASCICULARIS; MALE; NEURONS; RECEPTOR, ERBB-2; SPINE;

MACACA FASCICULARIS;

EID: 77953858502     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581810361527     Document Type: Article

References (33)

1. Kallioniemi OP, Holli K., Visakorpi T., Koivula T., Helin HH, Isola JJ Association of c-erb-B-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991 ; 49: 650-655.
2. Lin NU, Bellon JR, Winer EP CNS metastases in breast cancer. J Clin Oncol. 2004 ; 22: 3608-3617.
3. Altaha R., Crowell E., Hobbs G., Higa G., Abraham J. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer. 2005 ; 103: 442-443.
4. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 ; 97: 2972-2977.
5. Clayton AJ, Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004 ; 91: 639-643.
6. Pinder MC, Chang H., Broglio KR, et al. Trastuzumab treatment and the risk of central nervous system (CNS) metastases [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007 ; 25 (18 Suppl). 1018.
7. Stemmler HJ, Kahlert S., Siekiera W., Untch M., Heinrich B., Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006 ; 15: 219-225.
8. Yau T., Swanton C., Chua S., et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006 ; 45: 196-201.
9. Yardley DA, Kaufman PA, Mayer M., et al. RegistHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer. Poster 6049 presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007.
10. Doolittle ND, Peereboom DM, Christoforidis GA, et al. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the eleventh annual blood-brain barrier consortium meeting. J Neurooncol. 2007 ; 81: 81-91.
11. Altundag K., Altundag O., Atik MA, Morandi P., Gunduz M. Rationale for the use of trastuzumab in patients with cerebral metastases who previously received trastuzumab-based therapy for metastatic breast cancer. Breast. 2005 ; 14: 425.
12. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000 ; 18: 2350-2351.
13. Robins HI, Liu G., Hayes L., Mehta M. Trastuzumab for breast cancer-related carcinomatous meningitis. Clin Breast Cancer. 2002 ; 2: 316.
14. Stemmler HJ, Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007 ; 18: 23-28.
15. Colozza M., Minenza E., Gori S., et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol. 2009 ; 63: 1157-1159.
16. Ferrario C., Davidson A., Bouganim R., Aloyz R., Panasci LC Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol. 2009 ; 20: 792-795.
17. Laufman LR, Forsthoefel KF Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer. 2001 ; 2: 235.
18. Mir O., Ropert S., Alexandre J., Lemare F., Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncology. 2008 ; 19: 1978-1980.
19. Platini C., Long J., Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 2006 ; 7: 778-780.
20. Shojima K., Suzuki E., Saito K., et al. Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2008 ; 26 :Abstract 1138.
21. Stemmler HJ, Schmitt M., Harbeck N., et al. Application of intrathecal trastuzumab (Herceptintrade;) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep. 2006 ; 15: 1373-1377.
22. Stemmler HJ, Mengele K., Schmitt M., et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs. 2008 ; 19: 832-836.
23. Bergman I., Barmada MA, Griffin JA, Slamon DJ Treatment of meningeal breast cancer xenografts in the rat using an antiP185/HER2 antibody. Clin Cancer Res. 2001 ; 7: 2050-2056.
24. Grossi PM, Ochiai H., Archer GE Efficacy of intrathecal micro-infusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res. 2003 ; 9: 5514-5520.
25. Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol. 2003 ; 30: 49-53.
26. Rubenstein JL, Combs D., Rosenberg J. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003 ; 101: 466-468.
27. Perron J., Trudel Y., ́mond F., Simard H., Stilianesis M., Copeman C. Collection of cerebrospinal fluid by direct puncture or by surgically implanted ports in monkeys. Toxicologist. SOT 2008 Annual: 477.
28. Wood JH, Poplack DG, Bleyer WA, Ommaya AK Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. Science. 1977 ; 195: 499-501.
29. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharmaceut Res. 1993 ; 10: 1093-1095.
30. Siderov J. Care with intrathecal trastuzumab. Lancet Oncol. 2006 ; 7: 888.
31. Hetherington NJ, Dooley MJ Potential for patient harm from intrathecal administration of preserved solutions. Med J Aust. 2000 ; 173: 141-143.
32. Lin JH CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. 2008 ; 9: 46-59.
33. Blaney SM, Poplack DG, Godwin K., McCully CL, Murphy R., Balis FM Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995 ; 13: 177-179.